글로벌 전신성 홍반 루푸스 시장 - 2029년까지의 산업 동향 및 예측

시장 분석 및 통찰력 글로벌 전신성 홍반 루푸스 시장

전신성 홍반 루푸스 시장은 2022-2029년 예측 기간에 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 위에서 언급한 예측 기간에 시장이 7.55%의 CAGR로 성장할 것으로 분석하고 2029년까지 12억 7천만 달러에 도달할 가능성이 높습니다.

전신성 홍반 루푸스(SLE)는 자가면역 질환입니다. 신체의 면역 체계가 이 질환에서 실수로 건강한 조직을 파괴합니다. 피부, 관절, 신장, 뇌 및 기타 장기가 모두 영향을 받을 수 있습니다. SLE는 남성보다 여성에게 약 10배 더 흔합니다. 모든 연령대의 모든 사람에게 영향을 미칠 수 있습니다. 그러나 15세에서 44세 사이의 젊은 여성이 가장 흔히 영향을 받습니다. 이 질환의 징후와 증상에는 흉통, 피로, 림프절 부기, 발열, 전반적인 불편함, 불안, 탈모, 체중 감소, 구강 궤양, 햇빛에 대한 민감성 및 피부 발진 등이 있습니다.

전 세계적으로 전신성 홍반 루푸스 유병률의 증가는 전신성 홍반 루푸스 시장 확장의 주요 원동력이 될 것입니다. 또한, 노령 인구의 증가와 의료비 지출의 증가는 전신성 홍반 루푸스 시장을 확대할 요인입니다. 생활 방식의 변화와 염증성 자가면역 질환 및 질병 진단 치료에 대한 인식 증가를 포함한 다른 요인은 시장 성장률에 긍정적인 영향을 미칠 것입니다. 또한, 의료 기술의 발전, 정부 자금 지원 증가, 가처분 소득 수준의 증가는 전신성 홍반 루푸스 시장의 성장률을 가속화할 요인입니다.

Moreover, the rise in the research and development activities, launch of effective therapies and emerging new markets will provide beneficial opportunities for the systemic lupus erythematosus market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate of market in future.

However, high cost associated with the treatment and lack of infrastructure in low-income countries will impede the growth rate of market. Additionally, complications involved with disease will hinder the market growth. Less awareness will further challenge the market in the forecast period mentioned above.

This systemic lupus erythematosus market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the systemic lupus erythematosus market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Systemic Lupus Erythematosus Market Scope and Market Size

The systemic lupus erythematosus market is segmented on the basis of treatment type, diagnosis, dosage form, route of administration, symptoms, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of treatment type, the systemic lupus erythematosus market is segmented into antimalarial drugs, non-steroidal anti-inflammatory drugs, cytotoxic and immunosuppressive drugs, disease-modifying anti-rheumatic drugs, monoclonal antibodies, anticoagulants, biologics, others.
• On the basis of diagnosis, the systemic lupus erythematosus market is segmented into blood tests, urinalysis, and chest x-ray. Blood tests are further sub-segmented into antibody tests and a complete blood count.
• On the basis of dosage form, the systemic lupus erythematosus market is segmented into tablet, capsule, injection and others.
• Based on route of administration, the systemic lupus erythematosus market is segmented into oral, intravenous, subcutaneous.
• Based on symptoms, the systemic lupus erythematosus market is segmented into chest pain, fatigue, swollen lymph nodes, fever, general discomfort, uneasiness, hair loss, weight loss, mouth sores, sensitivity to sunlight, skin rash and others.
• On the basis of end-users, the systemic lupus erythematosus market is segmented into clinic, hospital and others.
• The systemic lupus erythematosus market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Systemic Lupus Erythematosus Market Country Level Analysis

Systemic lupus erythematosus market is analyzed and market size information is provided by the country, treatment type, diagnosis, dosage form, route of administration, symptoms, end-users and distribution channel as referenced above.

The countries covered in the systemic lupus erythematosus market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the systemic lupus erythematosus market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increase in the adoption of advanced technologies, changing lifestyle and growing population in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Systemic lupus erythematosus market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

경쟁 환경 및 글로벌 전신성 홍반 루푸스 시장 점유율 분석

전신성 홍반 루푸스 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 임상 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 포함됩니다. 위에 제공된 데이터 포인트는 전신성 홍반 루푸스 시장 조사와 관련된 회사의 초점에만 관련이 있습니다.

전신성 홍반 루푸스 시장의 주요 기업으로는 Bristol-Myers Squibb Company, Merck & Co., Inc., ImmuPharma PLC, GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Anthera Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc., Merck & Co., Lycera, Mylan NV, Sanofi, Aurinia Pharmaceuticals Inc., Sandoz International GmbH, Novartis AG, Bayer AG, Zydus Cadila, Corbus Pharmaceuticals Holdings Inc., Trinity Biotech, EUROIMMUN AG, bioMérieux SA, Quest, Bio-Rad Laboratories Inc. 등이 있습니다.

SKU-26334